Provided by Tiger Trade Technology Pte. Ltd.

BRII-B

0.910
+0.0101.11%
Volume:122.50K
Turnover:110.40K
Market Cap:657.02M
PE:-2.52
High:0.940
Open:0.890
Low:0.890
Close:0.900
52wk High:2.340
52wk Low:0.890
Shares:722.00M
HK Float Shares:722.00M
Volume Ratio:0.24
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.361
ROE:-7.67%
ROA:-7.02%
PB:0.25
PE(LYR):-2.52
PS:16.12

Loading ...

Brii Bio Announces Topline End-of-treatment Data from Phase 2B Enrich and Enhance Studies for the Treatment of Chronic Hepatitis B

THOMSON REUTERS
·
Jul 03

BRII-B Reports End-of-Treatment Topline Data from Phase 2b ENRICH and ENHANCE Studies for Chronic Hepatitis B

Stock News
·
Jul 03

Brii Biosciences Says Arbitration with Vir Clouds Future of Elebsiran Program

Reuters
·
Jul 03

Wuxi XDC Appoints Yuan Fang Joint Company Secretary, Authorized Representative

Reuters
·
Jun 26

HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%

Tiger Newspress
·
Jun 23

Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million

Reuters
·
Jun 17

BRII-B Announces Share Buyback Initiative

Stock News
·
Jun 17

Brii Biosciences Announces HK$60 Million On-Market Share Buy-back, Capping at 10% of Issued Shares

Bulletin Express
·
Jun 17

Brii Biosciences - to Buy Back up to 10% of Issued Shares

THOMSON REUTERS
·
Jun 17

Brii Biosciences Ltd - Share Buy-Back Programme Is No More Than HK$60 Mln

THOMSON REUTERS
·
Jun 17

Brii Biosciences shareholders adopted resolutions at annual general meeting, poll results show

Reuters
·
Jun 16

HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%

Tiger Newspress
·
Jun 05

Brii Bio says Phase 2 ENSURE trial shows higher HBV functional cure rate with elebsiran plus pegylated interferon alfa

Reuters
·
May 27

BRII-B (02137) and Vir Yet to Settle Claims in Ongoing Dispute

Stock News
·
May 22

BRII-B Initiates Arbitration Against Vir Biotechnology, Casting Uncertainty Over Elebsiran Hepatitis B Program

Bulletin Express
·
May 22

Brii Biosciences Ltd - as of May 22, Arbitration Between Brii and Vir Remains in Early Stages With No Resolution

THOMSON REUTERS
·
May 22

Brii Biosciences Ltd - Considers Elebsiran Program Future Uncertain Due to Ongoing Dispute

THOMSON REUTERS
·
May 22

Brii Biosciences - Cannot Invest in Phase 3 Clinical Study of Any Elebsiran-Containing Combination Therapy for Hbv Until Claims Are Resolved

THOMSON REUTERS
·
May 22

Brii Biosciences says arbitration with Vir clouds elebsiran hepatitis B program future

Reuters
·
May 22

Biotech Stocks Plunge Amid Global Bond Selloff and Rising Interest Rate Concerns

Stock News
·
May 18